HOME >> BIOLOGY >> NEWS
EPA Should Redirect Some Research on Toxic Airborne Particles

WASHINGTON -- As the Environmental Protection Agency (EPA) tightens standards for airborne particulates, it should redirect some research and maintain an integrated study program ensuring that the most serious public health risks posed by the particles are addressed, says a new report by a committee of the National Research Council. To that end, EPA should devote more funds to studying the types of particles most likely to be harmful to human health, the ways the particles cause damage, and the levels of exposure people actually receive.

"Recent studies have consistently shown that airborne particles are somehow associated with adverse health effects, especially for people with heart and lung ailments," said committee chair Jonathan Samet, professor and chair, department of epidemiology, Johns Hopkins University School of Hygiene and Public Health, Baltimore. "But as the new standards begin to take effect, further research must be done to determine precisely which particles pose the greatest health risks, and how. Gathering this information should be of the highest priority. The results will greatly increase the likelihood that money spent on regulating and controlling particulates will fully protect public health."

EPA recently set stricter standards for particulate matter -- a broad class of materials that originate from industrial manufacturing processes, forest fires, automobile exhaust, fossil fuel combustion, wind erosion, and a variety of other sources. The standards were changed after several epidemiological studies found associations between exposure to the particles and serious health consequences, including the exacerbation of asthma and other respiratory tract diseases -- which in some cases were leading to premature deaths. The new standards, set last July, for the first time target particulates smaller than 2.5 microns in diameter. When inhaled, these tiny particles are more l
'"/>

Contact: Molly Galvin, Kristen Nye
news@nas.edu
202-334-2138
The National Academies
1-Apr-1998


Page: 1 2 3 4

Related biology news :

1. Should Roundup Ready soybeans be managed differently than conventional soybeans?
2. Should publicly funded research be free and available to the public?
3. Fine Toothed Combs, Not Chemicals, Should Be Used To Treat Head Lice
4. Iron Supplemented Formula Milk Should Be Free For Inner City Children Into Their Second Year Of Life
5. Should Great Apes Be Given Legal Rights?
6. Penn Researchers Prove "Short-Cut" Function Of Myelin Sheath Channel: BetterUnderstanding Of Myelin Should Lead To Therapies For Neuropathies
7. Adults Need To Increase Intake Of Folate; Some Women Should Take More
8. Drivers Should Pay More Of Environmental Costs, Report Says
9. Lactose-Intolerant People Should Drink More Milk, Expert Says
10. Infants, Toddlers Should Not Restrict Fat Intake, Experts Say
11. Bee Sting Treatment Should Emphasize Speed, Not Method Of Removal

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: EPA Should Redirect Some Research Toxic Airborne Particles

(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: